The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).

<h4>Background</h4>Although liver function tests (LFTs) are routinely measured in primary care, raised levels in patients with no obvious liver disease may trigger a range of subsequent expensive and unnecessary management plans. The aim of this study was to develop and validate a predic...

Full description

Saved in:
Bibliographic Details
Main Authors: David J McLernon, John F Dillon, Frank M Sullivan, Paul Roderick, William M Rosenberg, Stephen D Ryder, Peter T Donnan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0050965&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849727547758084096
author David J McLernon
John F Dillon
Frank M Sullivan
Paul Roderick
William M Rosenberg
Stephen D Ryder
Peter T Donnan
author_facet David J McLernon
John F Dillon
Frank M Sullivan
Paul Roderick
William M Rosenberg
Stephen D Ryder
Peter T Donnan
author_sort David J McLernon
collection DOAJ
description <h4>Background</h4>Although liver function tests (LFTs) are routinely measured in primary care, raised levels in patients with no obvious liver disease may trigger a range of subsequent expensive and unnecessary management plans. The aim of this study was to develop and validate a prediction model to guide decision-making by general practitioners, which estimates risk of one year all-cause mortality in patients with no obvious liver disease.<h4>Methods</h4>In this population-based historical cohort study, biochemistry data from patients in Tayside, Scotland, with LFTs performed in primary care were record-linked to secondary care and prescription databases to ascertain baseline characteristics, and to mortality data. Using this derivation cohort a survival model was developed to predict mortality. The model was assessed for calibration, discrimination (using the C-statistic) and performance, and validated using a separate cohort of Scottish primary care practices.<h4>Results</h4>From the derivation cohort (n = 95 977), 2.7% died within one year. Predictors of mortality included: age; male gender; social deprivation; history of cancer, renal disease, stroke, ischaemic heart disease or respiratory disease; statin use; and LFTs (albumin, transaminase, alkaline phosphatase, bilirubin, and gamma-glutamyltransferase). The C-statistic for the final model was 0.82 (95% CI 0.80-0.84), and was similar in the validation cohort (n = 11 653) 0.86 (0.79-0.90). As an example of performance, for a 10% predicted probability cut-off, sensitivity = 52.8%, specificity = 94.0%, PPV = 21.0%, NPV = 98.5%. For the model without LFTs the respective values were 43.8%, 92.8%, 15.6%, 98.1%.<h4>Conclusions</h4>The Algorithm for Liver Function Investigations (ALFI) is the first model to successfully estimate the probability of all-cause mortality in patients with no apparent liver disease having LFTs in primary care. While LFTs added to the model's discrimination and sensitivity, the clinical utility of ALFI remains to be established since LFTs did not improve an already high NPV for short term mortality and only modestly improved a very low PPV.
format Article
id doaj-art-b1d3e60c06e64267b6c030c2c1a80f91
institution DOAJ
issn 1932-6203
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-b1d3e60c06e64267b6c030c2c1a80f912025-08-20T03:09:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5096510.1371/journal.pone.0050965The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).David J McLernonJohn F DillonFrank M SullivanPaul RoderickWilliam M RosenbergStephen D RyderPeter T Donnan<h4>Background</h4>Although liver function tests (LFTs) are routinely measured in primary care, raised levels in patients with no obvious liver disease may trigger a range of subsequent expensive and unnecessary management plans. The aim of this study was to develop and validate a prediction model to guide decision-making by general practitioners, which estimates risk of one year all-cause mortality in patients with no obvious liver disease.<h4>Methods</h4>In this population-based historical cohort study, biochemistry data from patients in Tayside, Scotland, with LFTs performed in primary care were record-linked to secondary care and prescription databases to ascertain baseline characteristics, and to mortality data. Using this derivation cohort a survival model was developed to predict mortality. The model was assessed for calibration, discrimination (using the C-statistic) and performance, and validated using a separate cohort of Scottish primary care practices.<h4>Results</h4>From the derivation cohort (n = 95 977), 2.7% died within one year. Predictors of mortality included: age; male gender; social deprivation; history of cancer, renal disease, stroke, ischaemic heart disease or respiratory disease; statin use; and LFTs (albumin, transaminase, alkaline phosphatase, bilirubin, and gamma-glutamyltransferase). The C-statistic for the final model was 0.82 (95% CI 0.80-0.84), and was similar in the validation cohort (n = 11 653) 0.86 (0.79-0.90). As an example of performance, for a 10% predicted probability cut-off, sensitivity = 52.8%, specificity = 94.0%, PPV = 21.0%, NPV = 98.5%. For the model without LFTs the respective values were 43.8%, 92.8%, 15.6%, 98.1%.<h4>Conclusions</h4>The Algorithm for Liver Function Investigations (ALFI) is the first model to successfully estimate the probability of all-cause mortality in patients with no apparent liver disease having LFTs in primary care. While LFTs added to the model's discrimination and sensitivity, the clinical utility of ALFI remains to be established since LFTs did not improve an already high NPV for short term mortality and only modestly improved a very low PPV.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0050965&type=printable
spellingShingle David J McLernon
John F Dillon
Frank M Sullivan
Paul Roderick
William M Rosenberg
Stephen D Ryder
Peter T Donnan
The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).
PLoS ONE
title The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).
title_full The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).
title_fullStr The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).
title_full_unstemmed The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).
title_short The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).
title_sort utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations alfi
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0050965&type=printable
work_keys_str_mv AT davidjmclernon theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT johnfdillon theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT frankmsullivan theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT paulroderick theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT williammrosenberg theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT stephendryder theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT petertdonnan theutilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT davidjmclernon utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT johnfdillon utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT frankmsullivan utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT paulroderick utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT williammrosenberg utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT stephendryder utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi
AT petertdonnan utilityofliverfunctiontestsformortalitypredictionwithinoneyearinprimarycareusingthealgorithmforliverfunctioninvestigationsalfi